Investorideas Updates Global #Stock Directories for Week of April 1, 2016: Additions in #Mining Sector Include #GreatLakesGraphite (TSXV: $GLK), #IntegraGold (OTC: $ICGQF; #TSXV: $ICG) and #INTLFCStone (NasdaqGS: $INTL)

Investorideas Updates Global #Stock Directories for Week of April 1, 2016:  Additions in #Mining Sector Include #GreatLakesGraphite (TSXV: $GLK), #IntegraGold (OTC: $ICGQF; #TSXV: $ICG) and #INTLFCStone (NasdaqGS: $INTL)

New York, NY; Point Roberts, WA – April 1, 2016 – Investorideas.com, a global news source and investor resource covering leading sectors announces this week’s additions to its global stock directories. The sector focus this week was  mining stocks.

This week’s profiled companies include Integra Gold (TSX:ICG.V; OTC: ICGQF) who was recently names to the TSX Venture top 50 performers in 2015 and the OTCQX Best 50 award for 2015; INTL FCStone (NasdaqGS:INTL), a leader in the development of specialized financial services in commodities and a member of both the London Metal Exchange (‘LME’) and NYMEX/COMEX and Great Lakes Graphite Inc. (TSX:GLK.V), an industrial minerals company focused on becoming a domestic manufacturer and supplier of graphite.

Companies added:

TSX Venture: Dunnedin Ventures Inc. TSX:DVI.V, Ecuador Gold & Copper Corp. TSX:EGX.V, Falco Resources Ltd. TSX:FPC.V, First Mining Finance Corp. TSX:FF.V, Gespeg Copper Resources Inc. TSX:GCR.V, IDM Mining Ltd. TSX:IDM.V, InZinc Mining Ltd. TSX:IZN.V,   GeoMegA Resources Inc. TSX:GMA.V, Gold Jubilee Capital Corp. TSX:GJB.V, Goldsource Mines Inc. TSX:GXS.V, Great Lakes Graphite Inc. TSX:GLK.V, Inca One Gold Corp. TSX:IO.V, Independence Gold Corp. TSX:IGO.V, International Millennium Mining Corp. TSX:IMI.V

Australia Stock Exchange (ASX) Listed: Global Geoscience Ltd. ASX:GSC.AX

Dual Listed: Integra Gold Corp. (TSX:ICG.V; OTC:ICGQF) is a junior gold exploration company advancing projects in Val-d'Or, Québec, one of the top mining jurisdictions in the world. The Company's primary focus is its high-grade Lamaque South project. Integra was recently named to the TSX Venture top 50 performers in 2015 and the OTCQX Best 50 award for 2015.

Nasdaq Listed: INTL FCStone (NasdaqGS:INTL) including its subsidiaries, is a leader in the development of specialized financial services in commodities, securities, global payments, foreign exchange and other markets.  METALS: As a ring-dealing member of the London Metal Exchange (‘LME’) and a member of NYMEX/COMEX, our metals futures, options and swaps capabilities are designed for the specific needs of our diverse customer base from CTAs and hedge funds to commercial producers, consumers and merchants. We offer 24-hour trade execution and clearing services through our operations in New York, London, Sydney and Chicago. We specialize in aluminum, copper, zinc, lead, nickel, tin and a suite of ferrous products including US hot-rolled coil, LME Billet, Chinese steel rebar, steel billet FOB Black Sea, US Midwest No. 1 busheling, HMS 80/20 ferrous scrap CFR Turkey, Turkish import scrap swaps, and iron ore swaps.

Profiled Companies:

INTL FCStone (NasdaqGS:INTL) including its subsidiaries, is a leader in the development of specialized financial services in commodities, securities, global payments, foreign exchange and other markets.  METALS: As a ring-dealing member of the London Metal Exchange (‘LME’) and a member of NYMEX/COMEX, our metals futures, options and swaps capabilities are designed for the specific needs of our diverse customer base from CTAs and hedge funds to commercial producers, consumers and merchants. We offer 24-hour trade execution and clearing services through our operations in New York, London, Sydney and Chicago. We specialize in aluminum, copper, zinc, lead, nickel, tin and a suite of ferrous products including US hot-rolled coil, LME Billet, Chinese steel rebar, steel billet FOB Black Sea, US Midwest No. 1 busheling, HMS 80/20 ferrous scrap CFR Turkey, Turkish import scrap swaps, and iron ore swaps.

Integra Gold Corp. (TSX:ICG.V; OTC:ICGQF) is a junior gold exploration company advancing projects in Val-d'Or, Québec, one of the top mining jurisdictions in the world. The Company's primary focus is its high-grade Lamaque South project. Integra was recently named to the TSX Venture top 50 performers in 2015 and the OTCQX Best 50 award for 2015.

Great Lakes Graphite Inc. (TSX:GLK.V) is an industrial minerals company focussed on bringing value-added carbon products to a well-defined market. The Company's Innovation Division has entered into long-term agreements for use of the Matheson Micronization Facility and for supply of high quality natural graphite concentrate which have positioned Great Lakes Graphite to become an emerging domestic manufacturer and supplier of micronized products to a growing regional customer base where pricing and demand continue to rise.

Investorideas.com features news and stock directories covering mining stocks, biotech stocks, water stocks, renewable energy, tech and other headline investing sectors.  

Coverage includes NASDAQ, TSX, NYSE, OTC and global stock exchanges.

About Investorideas.com - Big Ideas for Global Investors

InvestorIdeas.com  is a digital news source and investor resource covering leading sectors.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:

From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

http://www.investorideas.com/membership/

Services for Publily traded companies : http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Contact Investorideas.com

800-665-0411

Tech Stocks:NXT-ID (NASDAQ: NXTD) to Host 2015 Year End Discussion and 2016 Outlook Investor Webcast April 4, 2016

NXT-ID (NASDAQ: NXTD) to Host 2015 Year End Discussion and 2016 Outlook Investor Webcast April 4, 2016

MELBOURNE, Fla. - March 29, 2016 -- (Investorideas.com Newswire) NXT-ID, Inc. (NASDAQ:NXTD) ("NXT-ID" or the "Company"), a company focused on the growing mobile commerce market, announces it will host an investor webcast on Monday April 4, 2016 at 4:15 PM EDT. The Company will discuss its progress and results in 2015 and its strategy and outlook for 2016.

The webcast will be moderated by SoundView Technology Group analyst, Steve Waite. Also on the call with Gino Pereira, CEO of NXT-ID, will be NXT-ID directors, Stan Washington and Dr. Mike Remedios, who is also Chief Technology Officer at WorldVentures LLC.

Stan spent 17 years as an executive at American Express and was Regional Vice President and General Manager of the Western United States operating as the region's senior business leader where he managed American Express' U.S. Commercial Card Division overseeing the Account Development Organization including sales and operational support across multiple industries, to more than 260 U.S. based companies, representing over $300 billion in annual corporate revenue.

As Chief Technology Officer at World Ventures, Mike will give an overview of the strategic alliance between World Ventures and NXT-ID. Prior to joining World Ventures he was Chief Information Officer for Arbonne International, a billion dollar global cosmetics company, a Vice-President at Expedia, Inc. and Chief Technology Officer for Realtor.com and Shopping.com, a subsidiary of eBay, Inc. At eBay he was a member of the eBay Inc. Technology Board for eBay, PayPal and Skype.

Read this release in full at http://www.investorideas.com/CO/NXT/news/2016/03291.asp

Webcast Details:

Apr 4, 2016 at 4:15 PM EDT

Participants can register for the event at this link: http://edge.media-server.com/m/p/c8nomvhy

The webcast call will be recorded and available for playback at NXT-ID's website:

http://www.nxt-id.com.

About WorldVentures

WorldVentures Marketing, LLC is the leading international direct seller of vacation club memberships and helps people achieve more fun, freedom and fulfillment through their DreamTrips memberships which offer highly curated vacation, local entertainment, dining and event experiences enjoyed with the member community or individually. WorldVentures is a privately held company based in Plano, Texas, with active Representatives and Members in 28 countries. For more information, please visit http://www.worldventures.com

About NXT-ID

NXT-ID is an emerging growth technology company that is focused on products, solutions, and services for security on mobile devices. Our core technologies consist of those that support digital payments, biometric identification, encryption, sensors, and miniaturization. We have three distinct lines of business that we are currently pursuing: mobile commerce, primarily through the application of secure digital payment technologies; biometric access control applications, and Department of Defense contracting. Our initial efforts have primarily focused on the development of our secure products for the growing m-commerce market, most immediately, a secure mobile electronic smart wallet, the Wocket®. The Wocket® is a smart wallet, designed to protect your identity.

Product images are available for media at: http://press.nxt-id.com

Forward-Looking Statements for NXT-ID: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.

NXT- ID Inc Contact:

Corporate info: info@nxt-id.com

Media:

D. Van Zant
+1-800-665-0411
press@nxt-id.com

Visit this company: nxt-id.com; 3d-id.net; wocketwallet.com/

More info on NXTD at Investorideas.com Visit: http://www.investorideas.com/CO/NXT/

This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders

Sign up for free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: As of October 1, 2015 NXT-Id renewed for one year –five thousand per month and fifteen thousand 144 restricted shares for PR, media and marketing. http://www.investorideas.com/About/Disclaimer.asp and http://www.investorideas.com/About/News/Clientspecifics.asp

President of Q BioMed Inc. Expands on Corporate Update in Q&A

President of Q BioMed Inc. Expands on Corporate Update in Q&A

 

Denis Corin Discusses Mannin Research Inc’s Leading Glaucoma Drug Candidate MAN-01

 

 

March 21 , 2016 Point Roberts WA -  Investorideas.com, a digital global news source covering leading sectors including medical technology and biotech stocks releases a recent interview with Mr. Denis Corin, President of Q BioMed Inc. (OTCQB:QBIO).  Denis expands on the recent corporate update and Scrip Intelligence Video released in late February. He also comments on recent developments with Mannin Research Inc’s leading glaucoma drug candidate MAN-01.  (In October 2015 Q BioMed Inc. entered into an agreement with Mannin Research to exclusively license, with an option to acquire, the platform technology assets of Mannin Research, the developer of a new class of vascular therapeutics.)

 

Q&A
Q: Investorideas.com

Denis, your company’s strategy is to acquire companies and biomedical assets. Can you expand on that and also share what assets have been acquired or licensed to date?

 

A: Mr. Denis Corin, President of Q BioMed Inc.

Sure, our mission is to license and acquire innovative life sciences assets from academia or small private companies and provide the strategic resources including financial capital, intellectual capital, business development and scientific advice to accelerate their product development timelines to commercialize their drug candidates or bring them to the next level in terms of valuation inflection.

 

We have identified several targets that we believe could provide a substantial pipeline of innovative and high value assets. We will aim to maximize risk-adjusted returns by focusing on multiple assets throughout the discovery and development cycle, so we’ll have assets in pre-clinical, clinical and commercial stages. This allows a nice flow of development news and value drivers as they all move through their paces. We expect to benefit from early positioning in illiquid and/or unknown private assets with multiple potential products in their development cycle and to capitalize on valuation growth as they move forward in their development. We believe this gives investors a unique opportunity to participate in the growth and development of these assets and the value they bring to the overall pipeline.

 

In the last quarter of 2015, we entered into an exclusive License and Purchase Option Agreement with Mannin Research Inc. whereby we were granted a worldwide, exclusive license, with the option to acquire their platform assets for Glaucoma and other indications. The Mannin IP and technology platform is initially focused on developing a first-in-class eye drop treatment for glaucoma. The technology platform may be expanded in scope beyond Glaucoma as well as beyond ophthalmological uses and may include cystic kidney disease and others.

 

This is an area of therapy that urgently needs a new offering. No new drugs in this particular indication have been successfully brought to this market for over 20 years.

 

The global market for Glaucoma therapeutics is one of the largest segments of the $23 billion global ophthalmology market.  There are 60 million people worldwide suffering from Glaucoma.  It is projected that the total population suffering from Glaucoma will grow to 80 million by 2020 (W.H.O 2010), so there is an acute need for this type of drug in a very lucrative market. Our lead candidate, MAN-01, will address this market as a first-in-class drug that treats abnormal vessels within the eye, thereby treating Glaucoma at its root causes. 

 

There is no cure for Glaucoma and new therapeutics are highly sought after. Current therapies and surgical procedures are not optimally effective, are painful and not well tolerated by patients.

 

Together with Mannin, we are developing a unique molecule in the form of an easy-to-administer eye drop, designed to repair the normal flow of fluid in the eye and resulting in the reduction of intraocular pressure (IOP), one of the main causes of Glaucoma. Our platform is both unique and first-in-class and we are the only drug company targeting this method of action.

 

IOP caused by abnormal flow of clear fluid within the eye damages the nerves in the eye, eventually leading to blindness. A specialized blood vessel, the ‘Schlemm’s Canal’ is the major drainage pathway for fluid to escape from the front of the eye. Glaucoma can occur when this canal is either blocked or from a birth defect, resulting in a small or absent Schlemm’s Canal. Our drug candidate would target the organization of the Schlemms Canal on a cellular level, thereby creating the optimal environment for ‘repair’ and improved flow and ultimately, lower IOP.

 

Given the large 23 Billion dollar ophthalmology market and the acute need for these types of drugs, we believe there is a substantial opportunity here. In addition, a deep pipeline of novel therapeutics can be developed from this research platform, developed and lead by Dr. Quaggin, which would treat a spectrum of vascular diseases including Cystic Kidney disease.

 

So to sum up, while this is an earlier stage pre-clinical asset, we see tremendous opportunity here and look forward to building value in it as we advance.

 

 

Q: Investorideas.com

Can you tell us about your recent addition to management, Mr. David Laskow-Pooley, as VP Scientific & Product Development, and the value added to your team in seeking new products for your pipeline?

 

A: Mr. Denis Corin, President of Q BioMed Inc.

David is an industry veteran with a very broad-based and deep knowledge. We are very pleased to have him on board with us. He has 30 years of experience in all aspects of the discovery, development and commercialization of pharmaceutical products, diagnostics and devices. He has a distinguished career working for numerous pharmaceutical and life sciences companies. David has held director, executive officer and general management posts in both small and major multinational companies including GSK, Abbott, Amersham plc, Life Technologies, OSI, Bilcare and Surface Therapeutics.

 

David brings tremendous operational value to us as we look at commercializing assets and advancing them through the development life cycle. He has some very deep and unique experiences that will fit perfectly with some of the assets we are currently evaluating.

 

 

Q: Investorideas.com

Can you talk about Mannin Research Inc’s Glaucoma treatment technology and its lead drug candidate MAN-01 and the progress it is making?

 

A: Mr. Denis Corin, President of Q BioMed Inc

Mannin Research’s (Mannin) Glaucoma therapeutic is a first-in-class therapeutic designed to treat Primary Open-Angle Glaucoma. It is based on the research by Dr. Susan Quaggin, Director of the Feinberg Cardiovascular Research Institute and Chief of the Division of Nephrology and Hypertension at Northwestern University. The MAN-01 therapeutic is an important molecule in the context of new pharmaceuticals that can treat Glaucoma. Mannin’s therapeutic will address increased intraocular pressure in the eye by acting on a vessel in the eye called the Schlemm’s Canal, which is a main drainage path for the eye. Mannin is currently in the pre-clinical phase. Optimizing the molecule, we aim to use it in the clinic in late 2017/early 2018. There we are looking at demonstrating the effectiveness of this therapeutic in lowering intraocular pressure (IOP). We are making good progress and are on track to meet our internal milestones.

 

 

Q: Investorideas.com

Aerie Pharmaceuticals, Inc. (Nasdaq: AERI) reported safety results recently from a trial testing its Glaucoma treatment. Can you give us a quick differentiation in technology and approach between Mannin’s MAN-01 and Aerie Pharmaceuticals treatment?

A: Mr. Denis Corin, President of Q BioMed Inc.

 Aerie’s approach to treatment in Glaucoma, like ours, is to reduce IOP, which is the gold standard in measuring the effectiveness of Glaucoma’s therapeutics. Aerie’s mechanism of action (MOA) is the Rock/NET pathway which acts primarily on the Tubercular Meshwork, best described as a ‘sieve’ that sits on top of the main drainage canal in the eye, the ‘Schlemms Canal’. If this ‘sieve’ becomes inelastic or degraded it inhibits the optimal flow of fluids to the drain. Imagine, if you will, a ‘leaf-guard’ on top of a gutter on the roof of your house.

 

Mannin’s approach is to reduce IOP by addressing the defective cellular makeup of the actual ‘drain or gutter’ responsible for 70-90% of the fluid movement. Just a small improvement in the performance of this important vessel can have a significant effect on fluid movement and reducing IOP. So we believe this is a very important area for therapeutic development which is currently not being addressed with existing or new therapeutics in the pipeline.

 

The technical description of this is described in Dr. Quaggin’s research published in the JCI 2014 paper (Thompson et all, JCI, 2014).

 

Q: Investorideas.com

In your recent update you stated it is your goal to have at least 3 asset transactions completed this year to expand and broaden your pipeline. Can you tell us what areas within your sector seem promising and what you are looking into?

 

A: Mr. Denis Corin, President of Q BioMed Inc.

We are not really looking in any area specifically. We are just hunting for good value in undervalued or undiscovered assets that we believe have great potential. That said, we have a few targets on our due diligence list now that we really like. The most likely to make the top of that short list is a revenue ready asset that we think could be a revenue generator in the first year and also has some very exciting indication expansion possibilities. We’d like to have one deal done in the next quarter and possibly one more by the end of the year.

 

We hope interested shareholders and potential shareholders will stay up to date on our progress and come along for the ride by visiting our website and sign up for out news updates.

 

 

About Q BioMed Inc. ( OTCQB:QBIO)

Q BioMed Inc. ("Q") is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need.

http://qbiomed.com

About Investorideas.com - Big Ideas for Global Investors

InvestorIdeas.com - digital media global news source, PR and social media in leading sectors.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Sign up for free news alerts at Investorideas.com

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Disclosure: QBIO has retained investorideas.com for PR, media, news publication and social media effective February 5th for three months: two thousand five hundred per month.

 

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

 

Contact Investorideas.com

800 665 0411

Zacks Small Cap Research Maintains Buy Rating on Aethlon Medical (AEMD); Valued at $18 Share

Zacks Small Cap Research Maintains Buy Rating on Aethlon Medical (AEMD); Valued at $18 Share

Point Roberts WA, NEW YORK, NY – November 23, 2015 - Investorideas.com, a global digital news source covering leading sectors including biotech and medical technology reports new equity research on Aethlon Medical, Inc. (AEMD) was released by ZACKS SMALL CAP RESEARCH last week.  Analyst Brian Marckx, CFA maintains a buy rating with the following notes: 

“Current market discount rate, calculated by CAPM is approximately 9%.  Based on our DCF model and a 9% discount rate, AEMD is valued at approximately $18/share.  We are maintaining our Buy rating.  See below for access to our updated report on AEMD.  “

Read this release in full at http://www.investorideas.com/CO/AEMD/news/2015/11231.asp

Operational Update:  Meets All 5 Objectives, Aethlon ADAPT, Additional Progress…

On the fiscal first quarter conference call in August management laid out five specific objectives that they planned to accomplish over the following months.  They successfully did so and went through each one on the Q2 call, which we have provided an update to below.  But in addition to meeting these goals the company also made parallel progress in not only further shoring up their operational capabilities in preparation for increased activities related to both the HCV and cancer applications but also made strides in broadening the scope of potential applications where their technology might be applied. 

A recap and update to the five objectives that the company laid out on the Q1 call in August….

- Collect an additional ~$200k under the DAPRA contract which relates to year 4.  Hope to be granted year 5 of the contract (which was subsequently awarded).  Accomplished with $186k collected in Q2 and DARPA year 5 awarded in September. 

- Submission of manuscript of the DETECT (Diagnosing and Evaluating Traumatic Encephalopathy Using Clinical Tests) study.  As a reminder, since late last calendar year Aethlon’s majority-owned subsidiary Exosome Sciences (ESI) has collaborated with Boston University’s CTE Center for the development of a blood-based diagnostic that would be able to identify CTE in living individuals.  ESI has used what they learned in how to isolate certain brain-specific biomarkers to evaluate blood samples collected by participants (former NFL players and a control group) enrolled in BU's DETECT study.  The study is the first on CTE funded by the NIH. Aethlon submitted the manuscript subsequent to the Q1 call.  Management noted on the Q2 call that they think it could be published within the next ~60 days.  As an aside, the night before AEMD’s earnings call there was a timely 60 Minutes story about BU’s CTE study and the blood-based diagnostic that AEMD’s Exosome Sciences is helping lead the development of. 

- Accelerate cancer study with University of California, Irvine.  As a reminder, in mid-April AMED announced that they entered an agreement with UC, Irvine to conduct an investigator-initiated study with various cancer types including breast, colorectal lung, head and neck and others.  Targeted enrollment is five patients in each of nine cancer types (45 patients total) including breast adenocarcinoma, colorectal, gastric and gastroesophageal, pancreatic, cholangiocarcinoma, lung, head and neck, melanoma and ovarian adenocarcinoma.  The proposed study protocol, Plasma Exosome Concentration in Cancer Patients Undergoing Treatment”, will monitor changes in circulating exosome levels and their association with cancer treatment and response to treatment.  In May AEMD announced that UC, Irvine Medical Center approved an IRB to commence the study.  AEMD noted on the Q2 call that this study has commenced and has now enrolled three patients so far.        

- Advance additional collaborations for Hemopurifier in cancer and infectious diseases.  As a reminder, Hemopurifier has shown potential utility in HCV, HIV, Ebola, other pandemic diseases, bioterror applications, cancer and other areas.  AEMD is clearly focused on deepening and broadening the potential applications that their device may have utility for.  In June the company announced an agreement with the India’s National Institute of Virology to commence testing of Hemopurifier for treatment of Chikungunya.  Management also noted on the Q2 call that they have initiated a research project with the National Center for Biodefense and Infectious Diseases to investigate the use of Hemopurifier in Venezuelan equine encephalitis.  AEMD has had a relationship with the National Center for Biodefense and Infectious Diseases for over ten years and this latest announcement appears to be further progress towards working with the center for applications of AEMD’s technology in addressing biological threats.  

- Initiate the U.S. HCV feasibility study and transition Dr. Stephen Fadem from principal investigator of the study to a medical advisory role within the company.  Subsequent to the Q1 call that transition was made and Dr. Ronal Ralph was brought on as the new principal investigator.  AEMD expects to hire two sub-principal investigators to help further accelerate the trial schedule.  And while progression of the study has been drawn out longer than initially anticipated, AEMD noted on the Q2 call that they expect to have the new study team trained after Thanksgiving and begin new patient enrollment in January.  

See the full report here: http://scr.zacks.com/files/Nov-19-2015_AEMD_Marckx.pdf

Additional equity research coverage is published on Investorideas.com from third party firms http://www.investorideas.com/Research/

About Aethlon Medical, Inc. (AEMD)

Aethlon Medical creates affinity biofiltration devices to treat life-threatening diseases. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a first-in-class device that targets the rapid elimination of infectious viruses and cancer-promoting exosomes from the circulatory system of treated individuals. U.S. clinical progression of Hemopurifier therapy is being advanced under an FDA approved clinical study. We also provide government contracting services to the Defense Advanced Research Projects Agency related to the development of a biofiltration device to treat sepsis. Additional information can be found online at www.AethlonMedical.com or you can connect with us on Twitter, LinkedIn, Facebook and Google+.

InvestorIdeas.com is a global investor news source that follows the money in leading sectors including biotech and medical technology.  www.investorideas.com

Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: Investoridease.com has been compensated by AEMD for news publication and social media http://www.investorideas.com/About/Disclaimer.asp  and http://www.investorideas.com/About/News/Clientspecifics.asp   

Contact Investorideas.com

800 665 0411

JOIN Investorideas.com for Cyber Monday

JOIN Investorideas.com for Cyber Monday

50% off our annual membership – one year for just $48.50

Get Trading Ideas all year long for just over 0.13 a day!!!

 

Sign Up Now at http://www.investorideas.com/membership/cyber-monday.asp

 

Find great stocks in your favorite stock sector ... We have built lists of publicly traded stocks in each sector - microcap, small cap, large cap! We get you started... you find the ideas right for you!

From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

Just $48.50 a year

Sign Up Here

What do our Investor Ideas members get?

Exclusive Login access to our Global Stock Directories that are updated each month - thousands of stocks to research by sector...
Stocks listed may include the following stock exchanges: TSX, OTC, NASDAQ, NYSE, ASX, LSE – AIM, LSE – IRELAND, XETRA, FRANKFURT, BERLIN, EURONEXT, CHINA , HONG KONG, TOKYO, PARIS, MILAN, SPAIN, INDIA, MALAYSIA, SINGAPORE, MEXICO, ITALY, ARGENTINA, BRAZIL, TAIWAN, OSLO EXCHANGE (NORWAY), GREECE – ATHENS EXCHANGE, SWITZERLAND

*Due to the nature of the Investor Ideas members content, we do not offer trial memberships, in order to protect the proprietary stock directories. Therefore the membership is not refundable unless an incorrect purchase is made and we are notified immediately following the transaction the same day . Members are reminded the directories are for personal use only and not to be reproduced on other websites. Membership logins are not to be shared with other non- member users! Any violation of this will be taken very seriously.

Stock Directories Disclaimer

Investorideas.com paid stock directories are not guaranteed to be 100 % accurate but we do our best to update the directories and make edits and changes on a regular basis. Our stock directories do not include all publicly traded stocks within the sector but reflect a thorough representation of each sector we follow. All company descriptions are sourced from the company's public information.

About Investorideas.com - Big Ideas for Global Investors

InvestorIdeas.com - digital media global news source, PR and social media in leading sectors.

Sectors we cover include mining, energy, renewable energy, water stocks, food and beverage (including organic and LOHAS, wine), defense and security, biotech, technology and mobile. We have also recently expanded our global coverage to include Latin American stocks, the Middle East, sports and entertainment.

Disclaimer/Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: http://www.investorideas.com/About/Disclaimer.asp 

BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894

Contact Investorideas.com

800 665 0411

Investorideas.com Announces its First Global ‘Follow the Money’ Contest

Investorideas.com Announces its First Global ‘Follow the Money’ Contest

New York NY- Point Roberts WA–September 11, 2015 -- Investorideas.com (www.investorideas.com), a global investor news source covering leading sectors

announces its first ever ‘Follow the Money’ contest for global investors.

The contest will run from September 15^th to October 31^st, 2015 and is open to Investor Ideas members. (http://www.investorideas.com/membership/)

Prizes include a ‘Money Suit’ as seen worn by the Investorideas.com Money Team and also by Will Ferrell at the 2013 MTV Movie Awards.  Prizes also include Annual Small Cap Pro Accounts from Investor Hub http://investorshub.advfn.com/ with more prizes to be announced shortly.

The contest will consist of investors picking a stock or stocks they wish to buy within sectors they like and within the time frame of the contest (either real trades or fictional trades). Investors can buy their favorite beverage stock such as Starbucks Corporation (SBUX) from our beverage stock directory, their favorite Yoga Brand like Lululemon Athletica Inc. (LULU) from our LOHAS directory or Ralph Lauren Corporation (RL) from our Luxury Brand stock directory.

This contest gives investors a chance to not only invest in their favorite sectors and companies but also to test their skills against other global investors.  Investorideas.com stock directories feature and include stocks from most global stock exchanges. Key sectors covered include biotech, tech, mining, mobile, energy, water, defense and security, renewable energy, food and beverage stocks including wine stocks, luxury retail brands, sports stocks and others.

Rules and Eligibility: http://www.investorideas.com/membership/contest.asp

Read this release in full at http://www.investorideas.com/news/2015/main/09111.asp

More Info about Small Cap Pro: Small Cap Pro provides online Level 2 quotes for active stock traders. Users receive live Level 2 data for both OTCBB stocks and Pink Sheets. You will be able to use the Level 2 order book to see the buying support and selling pressure. This info will help determine when is a good time to buy or sell the stock. The Level 2 tool is available on the website or in the mobile apps.

This package also provides Level 1 stock quotes for all the web site tools such as monitor watchlists, charts, portfolio, last 100 trades, and toplists. This wide range of access provides live stock quotes everywhere you go. The data is unlimited so you are finally free to explore the world of stocks to your heart's content. Let our tools help you analyze and find the next great stock. Don't miss another great trading opportunity

About InvestorIdeas.com:

InvestorIdeas.com is a global news source for investors following leading business sectors including biotech, tech, mining, mobile, energy, water, defense and security, renewable energy, food and beverage stocks, sports and entertainment and Latin American stocks.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas

Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Sign up for our free news alerts

http://www.investorideas.com/Resources/Newsletter.asp

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp

BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

To Sponsor the contest with your brand or service call or email

Dawn or Cali

dvanzant@investorideas.com , cvanzant@investorideas.com

800-665-0411 - Source – www.Investorideas.com